Actelion says lung drug macitentan submitted in Europe
ZURICH (Reuters) - Actelion has submitted heart and lung drug macitentan to European health regulators, the second major step for the drug the Swiss group is positioning as a viable successor to its current top seller. "The European Medicines Agency will now start the formal review process," Actelion said on Thursday. It plans to sell the drug under the brand name Opsumit. Actelion, which submitted the treatment to the U.S. health regulator a month ago, issued data last month showing macitentan prolonged overall survival by more than a third in a clinical trial. ...
Source: news.yahoo.com
No comments:
Post a Comment